Navigation Links
For Multiple Sclerosis Treatment, Prescriber Base for Genzyme's Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch
Date:5/30/2013

EXTON, Pa., May 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that over half of surveyed neurologists have prescribed Aubagio, the second oral disease-modifying agent (DMA) marketed for multiple sclerosis (MS), to at least one of their MS patients at six months post-launch. While this represents a significant increase in prescriber base from one and three months post-launch, it does trail that observed with Gilenya (according to LaunchTrends: Gilenya Wave 3) at the same stage of product launch. This difference in prescriber base between the two oral DMAs is reflected in a smaller Aubagio patient share among DMA-treated relapsing-remitting MS (RR-MS) patients compared with the six-month share reported for Gilenya. Nevertheless, initial uptake of Aubagio continues to be driven by the product's convenient once-daily, oral formulation, with the majority of patients initiated on Aubagio still coming from switches.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

With Biogen Idec's Tecfidera being approved days before current survey fielding, substantial press coverage was given to the comparative wholesale prices across the DMAs, with Aubagio being the least expensive. Data from the LaunchTrends: Aubagio Wave 3 report suggest that this information has not had the expected impact on neurologists' perceptions of Aubagio's cost as significantly more of the 73 surveyed neurologists now perceive Aubagio as being more expensive than the other DMAs compared with previous waves. Furthermore, while current prescribers continue to express high overall satisfaction with Aubagio, especially for its efficacy, they rate their satisfaction with the product's cost significantly lower than at three months post-launch. Qualitative
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
2. Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
3. Aushon to Launch New Multiplex Immunoassay Platform
4. Multiple Sclerosis Association of Americas MRI Institute Marks 10 Years of Helping Individuals with Multiple Sclerosis Obtain MRIs
5. Hearing Loss Could Lead to Multiple Chronic Diseases for Millions of Brits
6. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally
7. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
8. Life Technologies Develops Simplified SAME-DAY STEC Solution for Detecting Multiple Strains of E. coli in Ground Beef
9. Therapy Trends: Multiple Sclerosis
10. New International Survey Reveals Multiple Barriers to an Accurate and Timely Alzheimers Disease Diagnosis
11. Eutropics Pharmaceuticals signs $1.5M NCI/SBIR contract to develop companion diagnostic for guiding Multiple Myeloma treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, received official notification from the European Patent ... key patent supporting its iSONEP™ and ASONEP™ programs. ... patent No. 2087002, claims compositions of matter related ... lead compounds, iSONEP and ASONEP. Sonepcizumab is an ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis ... Foundation (HNF), both philanthropies, announced today the creation ... for the treatment of the rare disease known ... Alliance announced its alliance model earlier this month. ... demonstration of a collaborative model where researchers and ...
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... a blood test improve,treatment outcomes for colorectal cancer ... management --,measuring drug levels in patients, blood and ... severe toxicity and improve efficacy in,colorectal cancer., ... cancer patients, by,Erick Gamelin, M.D., Ph.D. et. al., ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... Association annual meeting the results of,a Phase 2a ... of acute agitation in schizophrenic patients. The poster,presentation, ... (Presentation NR5-032), will be available for,viewing at the ...
Cached Medicine Technology:Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer 2Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer 3Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer 4Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer 5Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting 2
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... and is performed without anesthesia , , WEDNESDAY, Oct. 3 ... of an innovative form of colonoscopy that relies on ... , When it comes to detecting polyps that ... as effective as the traditional approach of using a ...
... It cuts rates of hospitalizations and deaths, study finds, , , WEDNESDAY, ... an annual flu shot will reduce the risk you,ll be hospitalized ... flu-related death by 48 percent. , That,s the conclusion of new ... England Journal of Medicine . , "This is a bad disease ...
... Calif., Oct. 3 Abaxis, Inc.,(Nasdaq: ABAX ... analysis systems, announced today the launch of the ... the Piccolo xpress(TM) point of,care analyzer. The ... imaging and,radiology centers in the United States to ...
... Acceptance of Umbilical Cord Blood Stem Cells as a Curative ... ... Inc. has been named,to Deloitte,s prestigious Technology Fast 50 Program for ... life sciences companies in the area by Deloitte & Touche USA ...
... CHICAGO, Oct. 3 President Bush,s veto today,of ... for millions of,children from families with low incomes ... dental health, says Oral Health America, a national,advocacy ... ten million children eligible for coverage through a,bipartisan, ...
... regarded as a barometer of a populations general health ... rate in 2006 was 5.9 infant deaths for every 1,000 ... made major progress in reducing infant deaths since the early ... but the decline has leveled off in recent years. The ...
Cached Medicine News:Health News:'Virtual' Colonoscopy an Effective Option: Study 2Health News:'Virtual' Colonoscopy an Effective Option: Study 3Health News:Flu Vaccine Does Protect Older People 2Health News:Flu Vaccine Does Protect Older People 3Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 2Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 3Health News:StemCyte, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los Angeles 4Health News:SCHIP Veto a Big Cavity for Children's Oral Healthcare, Advocates Say 2Health News:New York City's infant mortality rate declined in 2006 2Health News:New York City's infant mortality rate declined in 2006 3Health News:New York City's infant mortality rate declined in 2006 4
... The Aisys Carestation helps you deliver unmatched ... Aisys Carestation is the most complete anesthesia ... point of need - at your fingertips., ... our industry-leading Datex-Ohmeda legacy of anesthesia delivery ...
... Mesh LP is a super-light polypropylene mesh ... body reaction is reduced considerably. Optilene Mesh ... all open hernia repair procedures. It perfectly ... flexibility Optilene Mesh LP adapts to the ...
... Optilene Mesh Elastic is a lightweight and ... elasticity the mesh is able to adapt to ... The new honeycomb like structure with the large ... elastic scar. The mesh is ideal for incisional ...
... LP is a lightweight polypropylene mesh ... considerably reduced,foreign body reaction. The softer, ... It perfectly conforms to,anatomical structures. Due ... LP adapts to the movements of ...
Medicine Products: